Short Interest in CalciMedica Inc. (NASDAQ:CALC) Grows By 497.8%

CalciMedica Inc. (NASDAQ:CALC) was the target of a significant growth in short interest in June. As of June 30th, there was short interest totaling 1,651,945 shares, a growth of 497.8% from the June 15th total of 276,326 shares. Approximately 17.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 6,188,729 shares, the days-to-cover ratio is presently 0.3 days.

CalciMedica Stock Performance

Shares of CalciMedica stock traded down $0.11 on Monday, reaching $0.82. 557,414 shares of the stock were exchanged, compared to its average volume of 1,199,018. The firm’s 50 day moving average is $0.79 and its 200-day moving average is $1.63. CalciMedica has a one year low of $0.46 and a one year high of $7.20. The firm has a market cap of $12.92 million, a PE ratio of -0.62 and a beta of 0.89.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CalciMedica in a research report on Tuesday, July 7th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $10.00.

Insider Buying and Selling

In related news, Director Fred A. Middleton acquired 248,972 shares of the stock in a transaction on Thursday, June 25th. The shares were purchased at an average price of $0.80 per share, for a total transaction of $199,177.60. Following the purchase, the director directly owned 1,063,272 shares in the company, valued at approximately $850,617.60. The trade was a 30.57% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 41.55% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CALC. Cetera Investment Advisers boosted its holdings in shares of CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares in the last quarter. 180 Wealth Advisors LLC increased its stake in shares of CalciMedica by 297.2% in the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock valued at $68,000 after purchasing an additional 94,650 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of CalciMedica by 45.0% during the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after buying an additional 39,775 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of CalciMedica during the 4th quarter worth $127,000. Finally, Envestnet Asset Management Inc. lifted its position in shares of CalciMedica by 58.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after buying an additional 34,386 shares during the last quarter.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.